UK markets closed

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.7400+0.0180 (+0.66%)
At close: 07:02PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-7.00%
S&P500 52-week change 322.38%
52-week high 33.1400
52-week low 31.7000
50-day moving average 32.4452
200-day moving average 32.3474

Share statistics

Avg vol (3-month) 31.41k
Avg vol (10-day) 32.48k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 8113.31M
% held by insiders 122.29%
% held by institutions 141.51%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,252.15%

Management effectiveness

Return on assets (ttm)-29.31%
Return on equity (ttm)-57.54%

Income statement

Revenue (ttm)12.99M
Revenue per share (ttm)0.08
Quarterly revenue growth (yoy)-77.10%
Gross profit (ttm)N/A
EBITDA -78.66M
Net income avi to common (ttm)-74.39M
Diluted EPS (ttm)-0.7050
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)129.24M
Total cash per share (mrq)0.74
Total debt (mrq)8.08M
Total debt/equity (mrq)7.05%
Current ratio (mrq)6.70
Book value per share (mrq)0.65

Cash flow statement

Operating cash flow (ttm)-77.93M
Levered free cash flow (ttm)-45.96M